Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BW-20805 in Adult Subjects With Hereditary Angioedema
NCT06846398Phase 2Active, not recruiting
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 6
01
Overview
A Phase 2 trial of BW-20805 in hereditary angioedema (HAE), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd.. Started Feb 2025; status: active, not recruiting.
02
Drugs
BW-20805
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT06846398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846398.